Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Adenosine Pathway Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ENTPD1/CD39 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ENTPD1/CD39 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View ENTPD1 Products |
| Gene Delivery | ENTPD1/CD39 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Crucial for cell-based enzymatic and flow cytometry assays. |
View ENTPD1 Products |
| Benchmark Ab | Anti-ENTPD1/CD39 (Sequence of IPH5201 / TTX-030) Recombinant positive control antibody for benchmark assays. |
View ENTPD1 Products |
| Validator | ENTPD1/CD39 siRNA Set For target knockdown validation and assay specificity controls. |
View ENTPD1 Products |
| Related Target A | NT5E/CD73 Downstream converter of AMP to immunosuppressive adenosine. Synergistic target in the purinergic pathway. |
View NT5E Products |
| Related Target B | ADORA2A Adenosine A2A Receptor. Downstream G-protein coupled receptor mediating immunosuppression on T-cells. |
View ADORA2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Preservation | HEK293 mammalian expression ensures correct folding and post-translational modifications of recombinant soluble CD39. |
| Subfamily Off-Target Screening | High-purity homolog panels (ENTPD2, ENTPD3, ENTPD8) available for strict counter-screening. |
| Lack of Controls | Sequence-verified biosimilars (based on clinical leads) available as functional benchmark controls. |
| Cell-Surface Conformation | Lentiviral vectors enable robust, native CD39 expression on target cells, bypassing VLP-associated instability. |
Live ENTPD1/CD39 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ENTPD1/CD39 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to bispecific constructs and combination regimens. As first-generation CD39-blocking therapies reach Phase I/II clinical trials, the next wave of R&D is targeting the dual blockade of the adenosine pathway (CD39 + CD73) and combinations with PD-(L)1 inhibitors to overcome cold tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Innate Pharma (IPH5201), AbbVie (TTX-030) | Advanced Solid Tumors, Lung Cancer, Colorectal Cancer | Enzymatic Inhibition Assay (Requires high-purity, active recombinant CD39 ECD) |
| Bispecific Antibody | AstraZeneca (MEDI1120), Roche | Immunotherapy-Resistant Tumors | Dual Binding & Cross-reactivity Validation (Requires CD39 and co-target proteins) |
| Small Molecule Inhibitors | Corvus Pharmaceuticals | Hematological Malignancies, Solid Tumors | High-Throughput Screening (Requires stable ENTPD1-expressing cell lines via Lentivirus) |